FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588194639> ?p ?o ?g. }

• W2588194639 abstract "Background According to the guidelines of the Burkina Faso National Malaria Control Programme, artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the first-line drugs for uncomplicated malaria treatments. However, in some contexts where individuals will experience more than 1 episode of clinical malaria per year, it is unknown to what extent giving any of these ACTs repeatedly is safe. In the framework of the activities of the West African Network for Antimalarial Drugs (WANECAM) network, we have compared the efficacy and tolerability of repeated use of dihydroartemisinin-piperaquine (DHA-PQ) or artesunate-pyronaridine (PYR) with artesunate-amodiaquine (ASAQ). Methods A randomised open-label parallel 3 arms trial was conducted to compare the efficacy of a three-day regimen of DHA-PQ and PYR with ASAQ. The trial involved children and adults with uncomplicated falciparum malaria. Participants were randomly assigned to one of the three treatment arms at the first clinical episode. During the subsequent clinical episodes, the same drug was administered. Follow-up duration was 42 days for each episode. Study duration was two years for each participant. Primary endpoints were the incidence rate of uncomplicated malaria over a period of 2 years and PCR corrected/uncorrected ACPR at day 28 and day 42. Safety parameters were also assessed. Results Of the 763 patients enrolled, the incidence rate of clinical malaria was 1.4, 1.2, and 1.5 episodes / person-year at risk in the ASAQ, DHA-PQ and PYRAMAX arms, respectively. The PCR-uncorrected efficacy at day 28 versus day 42 was: ASAQ 93.4% vs 79.5%; PYR 98.1% vs 74.8%; and DHA-PQ 99.5% vs 95.2%. Bronchitis, rhinitis, abdominal pain, cough, QTc prolongation, headache, and vomiting were registered as the main adverse events in each of the three groups. Conclusions The findings from our study support the current recommendations for using artemisinin-based combinations in the treatment of uncomplicated malaria in areas of high malaria transmission such as Burkina Faso." @default.
• W2588194639 created "2017-02-24" @default.
• W2588194639 creator A5010782141 @default.
• W2588194639 creator A5012502765 @default.
• W2588194639 creator A5013139296 @default.
• W2588194639 creator A5026047632 @default.
• W2588194639 creator A5033353997 @default.
• W2588194639 creator A5040533373 @default.
• W2588194639 creator A5040772126 @default.
• W2588194639 creator A5051669703 @default.
• W2588194639 creator A5051790261 @default.
• W2588194639 creator A5054067303 @default.
• W2588194639 creator A5066290105 @default.
• W2588194639 creator A5066318712 @default.
• W2588194639 creator A5069054013 @default.
• W2588194639 creator A5070091008 @default.
• W2588194639 creator A5087492146 @default.
• W2588194639 date "2017-02-01" @default.
• W2588194639 modified "2023-10-17" @default.
• W2588194639 title "EFFICACY AND TOLERABILITY OF REPEATED ADMINISTRATION OF ACTS OVER A PERIOD OF TWO YEARS IN CHILDREN AND ADULT PATIENTS WITH ACUTE UNCOMPLICATED MALARIA IN BURKINA FASO" @default.
• W2588194639 doi "https://doi.org/10.1136/bmjgh-2016-000260.48" @default.
• W2588194639 hasPublicationYear "2017" @default.
• W2588194639 type Work @default.
• W2588194639 sameAs 2588194639 @default.
• W2588194639 citedByCount "0" @default.
• W2588194639 crossrefType "journal-article" @default.
• W2588194639 hasAuthorship W2588194639A5010782141 @default.
• W2588194639 hasAuthorship W2588194639A5012502765 @default.
• W2588194639 hasAuthorship W2588194639A5013139296 @default.
• W2588194639 hasAuthorship W2588194639A5026047632 @default.
• W2588194639 hasAuthorship W2588194639A5033353997 @default.
• W2588194639 hasAuthorship W2588194639A5040533373 @default.
• W2588194639 hasAuthorship W2588194639A5040772126 @default.
• W2588194639 hasAuthorship W2588194639A5051669703 @default.
• W2588194639 hasAuthorship W2588194639A5051790261 @default.
• W2588194639 hasAuthorship W2588194639A5054067303 @default.
• W2588194639 hasAuthorship W2588194639A5066290105 @default.
• W2588194639 hasAuthorship W2588194639A5066318712 @default.
• W2588194639 hasAuthorship W2588194639A5069054013 @default.
• W2588194639 hasAuthorship W2588194639A5070091008 @default.
• W2588194639 hasAuthorship W2588194639A5087492146 @default.
• W2588194639 hasConcept C120665830 @default.
• W2588194639 hasConcept C121332964 @default.
• W2588194639 hasConcept C126322002 @default.
• W2588194639 hasConcept C197934379 @default.
• W2588194639 hasConcept C203014093 @default.
• W2588194639 hasConcept C2776120307 @default.
• W2588194639 hasConcept C2776992834 @default.
• W2588194639 hasConcept C2778048844 @default.
• W2588194639 hasConcept C2778059366 @default.
• W2588194639 hasConcept C2778371730 @default.
• W2588194639 hasConcept C2778375690 @default.
• W2588194639 hasConcept C2778629330 @default.
• W2588194639 hasConcept C2780780316 @default.
• W2588194639 hasConcept C2781160685 @default.
• W2588194639 hasConcept C2781413609 @default.
• W2588194639 hasConcept C535046627 @default.
• W2588194639 hasConcept C61511704 @default.
• W2588194639 hasConcept C71924100 @default.
• W2588194639 hasConceptScore W2588194639C120665830 @default.
• W2588194639 hasConceptScore W2588194639C121332964 @default.
• W2588194639 hasConceptScore W2588194639C126322002 @default.
• W2588194639 hasConceptScore W2588194639C197934379 @default.
• W2588194639 hasConceptScore W2588194639C203014093 @default.
• W2588194639 hasConceptScore W2588194639C2776120307 @default.
• W2588194639 hasConceptScore W2588194639C2776992834 @default.
• W2588194639 hasConceptScore W2588194639C2778048844 @default.
• W2588194639 hasConceptScore W2588194639C2778059366 @default.
• W2588194639 hasConceptScore W2588194639C2778371730 @default.
• W2588194639 hasConceptScore W2588194639C2778375690 @default.
• W2588194639 hasConceptScore W2588194639C2778629330 @default.
• W2588194639 hasConceptScore W2588194639C2780780316 @default.
• W2588194639 hasConceptScore W2588194639C2781160685 @default.
• W2588194639 hasConceptScore W2588194639C2781413609 @default.
• W2588194639 hasConceptScore W2588194639C535046627 @default.
• W2588194639 hasConceptScore W2588194639C61511704 @default.
• W2588194639 hasConceptScore W2588194639C71924100 @default.
• W2588194639 hasLocation W25881946391 @default.
• W2588194639 hasOpenAccess W2588194639 @default.
• W2588194639 hasPrimaryLocation W25881946391 @default.
• W2588194639 hasRelatedWork W1968329346 @default.
• W2588194639 hasRelatedWork W1974204803 @default.
• W2588194639 hasRelatedWork W2075267721 @default.
• W2588194639 hasRelatedWork W2090633875 @default.
• W2588194639 hasRelatedWork W2095632566 @default.
• W2588194639 hasRelatedWork W2099271248 @default.
• W2588194639 hasRelatedWork W2112658233 @default.
• W2588194639 hasRelatedWork W2123618955 @default.
• W2588194639 hasRelatedWork W2128483604 @default.
• W2588194639 hasRelatedWork W2150714660 @default.
• W2588194639 hasRelatedWork W2151167628 @default.
• W2588194639 hasRelatedWork W2151344802 @default.
• W2588194639 hasRelatedWork W2152960683 @default.
• W2588194639 hasRelatedWork W2262927268 @default.
• W2588194639 hasRelatedWork W2555838895 @default.
• W2588194639 hasRelatedWork W2612256533 @default.
• W2588194639 hasRelatedWork W2940781171 @default.
• W2588194639 hasRelatedWork W2952379735 @default.
• W2588194639 hasRelatedWork W3023462685 @default.
• W2588194639 hasRelatedWork W3170474881 @default.

• next